EGFR and neoplasm: Boeckx et al., in a retrospective analysis of study 20050181 (FOLFIRI-Panitumumab vs FOLFIRI) and study 20020408 (panitumumab vs best supportive care), investigated the efficacy of anti-EGFR-based therapy, after first-line, according to primary tumor location.